Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)
Sponsor: Samsung Medical Center
Listed as NCT02140463, this observational or N/A phase trial focuses on Genitourinary Cancer and Metastatic Gastrointestinal Cancer and remains completed. Sponsored by Samsung Medical Center, it has been updated 15 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
15 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jul 2022 — Jul 2024 [monthly]
Completed
Status: Unknown Status → Completed
-
Dec 2021 — Jul 2022 [monthly]
Unknown Status
▶ Show 10 earlier versions
-
Oct 2021 — Dec 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Recruiting
-
Jun 2019 — Nov 2020 [monthly]
Recruiting
-
Jun 2018 — Jun 2019 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Feb 2017 — Aug 2017 [monthly]
Recruiting NA
Status: Completed → Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Feb 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Samsung Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .